

Initial Date: 07/19/2023

Revised Date:

Section: 9-38R

---

## ***Ondansetron***

**Pharmacological Category:** Antiemetic

### **Indications:**

1. Nausea and vomiting

**Routes:** IV/IM; ODT (for patients  $\geq$  30 kg)

### **Contraindications:**

1. Patients with Phenylketonuria (PKU)

### **Precautions:**

1. Do not administer ODT to patients that are actively vomiting

### **Expected effects:**

1. Diminished nausea

### **Side effects:**

1. Headache
2. Dry mouth
3. Drowsiness

### **Notes:**

1. Orally Disintegrating Tablet (ODT) is an MCA optional medication and may not be available.

### **Dosing: NAUSEA & VOMITING**

Indication: Nausea & vomiting

#### Adults administer:

1. Ondansetron ODT 4mg if not actively vomiting and ODT is available.
2. Ondansetron 4mg IV/IM if patient is actively vomiting, vomited post ODT administration, or ODT is not available.
3. May administer a second dose of ondansetron 4 mg (IV/IM only). Total dose (including ODT) not to exceed 8 mg.

Initial Date: 07/19/2023

Revised Date:

Section: 9-38R

---

Pediatrics administer:

1. Ondansetron according to MI MEDIC cards
2. If MI MEDIC cards are not available administer:
  - a. Pediatrics  $\geq$  30 kg that is not actively vomiting and ODT is available administer:
    - i. Ondansetron 4 mg ODT
  - b. Pediatrics < 30 kg, or if the patient is actively vomiting, or if the patient vomited post OD administration, or ODT is not available, administer:
    - i. Ondansetron 0.1 mg/kg IV/IM, maximum dose of 4 mg.
  - c. May repeat ondansetron 0.1 mg/kg IV/IM, maximum dose of 4 mg. Total dose (including ODT) may not exceed 8 mg.

Used in the Following Protocol(s):

Nausea & Vomiting (Section 1 General Treatment)